Back to Search Start Over

The risk of new fragility fractures in patients with chronic kidney disease and hip fracture—a population-based cohort study in the UK

Authors :
T P van Staa
I. J. A. de Bruin
Patrick C. Souverein
J. van den Bergh
Caroline E. Wyers
F. de Vries
Johanna H M Driessen
Piet Geusens
Afd Pharmacoepi & Clinical Pharmacology
Pharmacoepidemiology and Clinical Pharmacology
Interne Geneeskunde
RS: NUTRIM - R3 - Respiratory & Age-related Health
RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation
RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome
MUMC+: DA KFT Medische Staf (9)
Farmacologie en Toxicologie
Source :
de Bruin, I J A, Wyers, C E, Souverein, P C, van Staa, T P, Geusens, P P M M, van den Bergh, J P W, de Vries, F & Driessen, J H M 2020, ' The risk of new fragility fractures in patients with chronic kidney disease and hip fracture-a population-based cohort study in the UK ', Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA . https://doi.org/10.1007/s00198-020-05351-x, Osteoporosis International, 31(8), 1487-1497. Springer-Verlag London Ltd., Osteoporosis International, Osteoporosis International, 31(8), 1487. Springer London
Publication Year :
2020
Publisher :
Springer Science and Business Media LLC, 2020.

Abstract

Summary Chronic kidney disease (CKD) is a risk factor for fractures. However, in hip fracture patients, CKD G3-G5 was associated with a higher mortality risk and not associated with a higher risk of subsequent non-hip fractures compared to eGFR > 60 ml/min. The higher mortality risk may, as competing risk, explain our findings. Introduction Chronic kidney disease (CKD) is a known risk factor for fragility fractures. Patients aged 50+ with a recent fragility fracture have an increased risk of subsequent fractures. Our aim was to evaluate the association between CKD stages G3–G5 versus estimated glomerular filtration rate (eGFR) > 60 ml/min and the risk of a new non-hip fracture or fragility fracture in patients with a first hip fracture. Methods Population-based cohort study using the UK general practices in the Clinical Practice Research Datalink. Associations between CKD stage and first subsequent fracture were determined using Cox proportional hazard analyses to estimate hazard ratios (HRs). To explore the potential competing risk of mortality, cause-specific (cs) HRs for mortality were estimated. Results CKD G3–G5 was associated with a lower risk of any subsequent non-hip fracture (HR: 0.90, 95%CI: 0.83–0.97), but not with the risk of subsequent major non-hip fragility fracture. CKD G3-G5 was associated with a higher mortality risk (cs-HR: 1.05, 95%CI: 1.01–1.09). Mortality risk was 1.5- to 3-fold higher in patients with CKD G4 (cs-HR: 1.50, 95%CI: 1.38–1.62) and G5 (cs-HR: 2.93, 95%CI: 2.48–3.46) compared to eGFR > 60 ml/min. Conclusions The risk of a subsequent major non-hip fragility fractures following hip fracture was not increased in patients with CKD G3–G5 compared to eGFR > 60 ml/min. Mortality risk was higher in both hip fracture and non-hip fracture patients with CKD G4 and G5. The higher mortality risk may, as competing risk, explain our main finding of no increased or even decreased subsequent fracture risk after a hip fracture in patients with CKD G3–G5. Electronic supplementary material The online version of this article (10.1007/s00198-020-05351-x) contains supplementary material, which is available to authorized users.

Details

ISSN :
14332965 and 0937941X
Volume :
31
Database :
OpenAIRE
Journal :
Osteoporosis International
Accession number :
edsair.doi.dedup.....a57f5eb9d31f09775b87e210bf58adf1
Full Text :
https://doi.org/10.1007/s00198-020-05351-x